Innate Pharma S.A. (IPHA)

Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	70.61	84.23	103.76	136.79	202.89
Short-Term Investments	21.85	17.26	16.08	14.85	15.98
Cash & Cash Equivalents	92.46	101.49	119.84	151.64	218.87
Cash Growth	-8.90%	-15.31%	-20.97%	-30.72%	30.64%
Receivables	66.11	52.45	48.24	51.64	35.48
Other Current Assets	-10.56	-14.1	-29.82	-29.82	-16.74
Total Current Assets	148.01	139.83	138.26	173.45	237.61
Property, Plant & Equipment	6.32	8.54	10.17	11.69	11.67
Long-Term Investments	9.8	35.12	39.88	38.93	37.01
Goodwill and Intangibles	0.42	1.56	44.19	46.29	96.97
Other Long-Term Assets	19.65	22.82	35	37.06	18.11
Total Long-Term Assets	36.18	68.03	129.24	133.97	163.76
Total Assets	184.19	207.86	267.5	307.42	401.36
Accounts Payable	17.02	20.91	28.57	29.54	49.5
Deferred Revenue	10.48	14.48	37.91	43.97	89.11
Current Debt	8.94	2.1	30.75	2.14	2.13
Other Current Liabilities	3.2	3.84	-17.35	-30.17	-18.92
Total Current Liabilities	39.64	41.34	79.89	45.49	121.82
Long-Term Debt	30.96	40.15	13.5	16.95	16.59
Other Long-Term Liabilities	61.7	72.23	66.67	89.01	45.53
Total Long-Term Liabilities	92.66	112.37	80.17	105.96	62.12
Total Liabilities	132.29	153.71	160.06	151.45	183.95
Total Debt	39.89	42.25	44.25	19.09	18.72
Debt Growth	-5.58%	-4.52%	131.84%	1.94%	314.04%
Retained Earnings	-336.89	-330.32	-272.21	-220.46	-155.67
Shareholders' Equity	51.9	54.15	107.44	155.98	217.42
Net Cash / Debt	52.56	59.23	75.59	132.55	200.14
Net Cash / Debt Growth	-11.26%	-21.63%	-42.98%	-33.77%	22.78%
Working Capital	108.38	98.49	58.37	127.96	115.78
Book Value Per Share	0.65	0.68	1.36	1.99	2.91

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).